EC OKs Roche MabThera (rituximab) for rare autoimmune disease

• MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease in more than 60 years
• PV is a rare and potentially life-threatening blistering condition which can cause severe pain and disfigurement
• MabThera is now approved in Europe to treat four autoimmune diseases

https://www.marketscreener.com/ROCHE-HOLDING-68997/news/Roche-European-Commission-approves-Roche-s-MabThera-rituximab-for-a-rare-autoimmune-disease-28170464/